<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6276">
  <stage>Registered</stage>
  <submitdate>20/01/2017</submitdate>
  <approvaldate>20/01/2017</approvaldate>
  <nctid>NCT03030430</nctid>
  <trial_identification>
    <studytitle>Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects</studytitle>
    <scientifictitle>Randomized, Double-blind, Single-dose, 3-arm Parallel Design Comparative Pharmacokinetic(PK) and Safety Study of BAT1706 Versus European Union(EU)-Sourced Avastin® and United State (US)-Sourced Avastin® Administered in Healthy Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BAT-1706-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>NSCLC</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - BAT1706
Other interventions - EU-sourced Avastin
Other interventions - US-sourced Avastin

Experimental: BAT1706 - BAT1706

Active Comparator: EU-sourced Avastin - EU-sourced Avastin

Active Comparator: US-sourced Avastin - US-sourced Avastin


Other interventions: BAT1706
1mg/kg, IV on day 1

Other interventions: EU-sourced Avastin
1mg/kg, IV on day 1

Other interventions: US-sourced Avastin
1mg/kg, IV on day 1

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>area under curve (AUC)0~8</outcome>
      <timepoint>4 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Adult males aged 18 to 50 years inclusive and body weight 65 to 100kg.

          2. Subjects who are healthy as determined by pre-study medical history, physical
             examination, vital signs and 12 ECG.

          3. Subjects whose clinical laboratory test results are normal, or where outside the
             reference range are judged as not clinical relevant.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Have a history of and/or current clinically significant gastrointestinal, renal,
             hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic, psychiatric
             or allergic disease excluding mild asymptomatic seasonal allergies.

          2. Subject with a psychiatric disorder or considered unsuitable for inclusion by the
             investigator.

          3. History or current clinically significant, excluding mild asymptomatic seasonal
             allergies, hypersensitivity or allergic reactions including known or suspected drug
             hypersensitivity to any component of the study drug formulations or comparable drugs.

          4. Any biological drug within 3 months or monoclonal antibodies within 9 months of study
             drug administration.

          5. Intake of herbal remedies within 14 days prior to study drug administration.

          6. History of alcohol abuse or a positive alcohol test on screening or admission to the
             clinical center.

          7. Any persons who are:an employee of the Principal Investigator, clinical center,
             Clinical Research Organization (CRO) or Sponsor;a relative of an employee of the
             clinical center, the Investigators, CRO or the Sponsor.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>15/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>129</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/06/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bio-Thera Solutions</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to establish PK similarity in the treatment of BAT1706 and
      comparators.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03030430</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Chris Wynne, Medical Doc</name>
      <address>Director</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Chris Wynne, Medical Doc</name>
      <address />
      <phone>+64 33729477</phone>
      <fax />
      <email>Chris@ccst.co.nz</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>